A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO CoV.617.1) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
PT Tigermed Consulting Indonesia
No Registry
INA-2ETBDZ8
Tanggal Input Registry : 19-07-2024

01-01-2022
not specified
 
A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO CoV.617.1) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines
A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO CoV.617.1) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines
Interventional
SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO CoV.617.1)
5
 

Inclusion Criteria:

not specified

Exclusion Criteria:

not specified
 
not specified
Not applicable
PPUK/PPUB number
not specified